Objective: To examine the efficacy of a combination of anticancer agents and cytokine-induced killer (CIK) cell therapy in inoperable pancreato-biliary cancer patients.Methods: We retrospectively reviewed the medical records of 17 inoperable pancreato-biliary cancer patients who were hospitalized from January 2015 to December 2019 in YCH hospital, Korea, and had received at least 5 treatments with CIK-cell therapy.The patients were all on chemotherapy.The major endpoints of the investigation were the overall survival time.Results: A total of 17 patients were enrolled, 8 (47.1%) males and 9 (52.9%)females (n = 17).The mean age was 61.7 ± 7.8 years.In types of cancer, the patients of pancreatic cancer were 6, and biliary tract were 11.At the survival time analysis, 8 patients (47.1%) were still alive, but death occurred in 9 patients (52.9%).The frequency of CIK-cell therapy was 8.2 ± 4.1.The overall median survival time was 553.0 ± 129.9 days (298.4 days -807.6 days) (by Kaplan-Meier Method) which was 6-9 months longer than conventional treatment alone. Conclusion:In this study CIK-cell therapy prolonged the survival of cancer patients without any major side effects when combined with anticancer drugs.A combination of Anticancer agents with cytokine-induced killer (CIK) cell can be a good proposal for improving the treatment outcomes for pancreatic and biliary cancer.
No takes yet. Share an insight, caveat, or question.
Jinsung et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: